Fas-1377A/G and FasL-844 T/C Gene Polymorphisms and Epithelial Ovarian Cancer
Background: The Fas receptor is known to be widely expressed in various tissues and FasL is highly expressed on cells of the immune system and also on cells of immune-privileged areas such as the eyes and brain. Ovarian cells are known to exhibit marked FasL immunoreactivity throughout follicular de...
Saved in:
Published in | Anticancer research Vol. 27; no. 2; pp. 991 - 994 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.03.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background: The Fas receptor is known to be widely expressed in various tissues and FasL is highly expressed on cells of the
immune system and also on cells of immune-privileged areas such as the eyes and brain. Ovarian cells are known to exhibit
marked FasL immunoreactivity throughout follicular development; there may also be a relationship between Fas and FasL polymorphisms
and the immune privileges of the epithelial ovarian cells. Patients and Methods: The study included 47 epithelial ovarian
carcinoma patients and 41 healthy subjects. Polymerase chain reaction (PCR) and restriction endonucleases were used to determine
the polymorphic Fas and FasL genes. Results: The FasL CC genotype was found to increase the risk of ovarian carcinoma and
a protective effect of the GGCT genotype was observed. Conclusion: Because of the expressional aspects of the FasL-844TâC
polymorphism, individuals carrying the FasL-844C allele would be expected to have higher FasL expression on tumour cells compared
with those carrying the FasL-844T allele. People with such a genotype show a tendency to develop various tumours. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |